Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

Pantethine is effective and well tolerated for treatment of dyslipidemia in adults, study shows


  • Pantesin® pantethine significantly reduces total and LDL-cholesterol and apolipoprotein B, compared to placebo.
  • Dosage is 600 mg/day (baseline to week 8), then 900 mg/day (weeks 9-16)
  • 300-mg, twice-per-day, dosing schedule effective for adults at low or moderate risk of CVD.
  • Pantethine is well tolerated, mild GI distress reported


This double-blind, placebo controlled trial involved 120 men and women at low or moderate risk for heart disease living in North America. Subjects followed a Therapeutic Lifestyle Change (TLC) diet 4 weeks before starting the study and maintained the diet throughout a 16-week study period. Subjects were randomly assigned to take Pantesin® HF pantethine or a placebo. The amount of pantethine was 600 mg/day (baseline to week 8) and 900 mg/day (weeks 9-16).

By week 16, pantethine significantly (P<.05) reduced total cholesterol (6 mg/dL, 3%), LDL cholesterol (4 mg/dL, 4%), and apolipoprotein B (4 mg/dL, 5%), compared to placebo. As early as week 2, pantethine produced significant decreases in total and LDL cholesterol, TC/HDL ratio, non-HDL, and apo-B, which were sustained throughout the 16-week study period. No significant between-group differences were found for apo-A, HDL cholesterol or triglyceride levels.

The dosage increase from 600 to 900 mg/day did not appear to provide any additional or measurable benefit, suggesting the optimal benefit in these low- to moderate-risk subjects is achieved at a 300-mg, twice-per-day, dosing schedule. Pantethine was well tolerated with a low frequency of side effects, primarily mild gastrointestinal complaints.

PANTESIN® is a registered trademark of Daiichi Fine Chemical Co., Ltd.


Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31(8):608-15.

PMID: 21925346